{"name":"Certa Therapeutics","slug":"certa-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPSXIwNlY4QXpwM1pSTThkajRZenBRWVFPMkVhYW45TkNVX2F3bUlFRFkyQmNTaHpPYy1xdlZTWXk2bHlJNkdNY3ZtR0hzb0NDbzFfMzBlRG5fUnhVSkxYU2lvNFpXM0FIWDNKWk9xWW1wR19qTFJUZExFOXZrdTVHbnVzNC1EemlkWnE2WXl0b0tnS1d5bjRsSWR3cVh4cnZ2Q2dRVVo3SXNLMC11dmJzWjRDeG1GY0FHdGtFNVVTcFNKZ09uNDVZWDl3RlVqdk5lSVJiSkdfbUY3bUUxQlJZLVhQaXZ2dzZLTzFWaXZwbkpCM2U4OThFU1JMSElnWE1ZTnc?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Systemic Sclerosis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Systemic Sclerosis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxOY3UwTFY2ZGI5ZXJNUEJVZ3o0ZThCdTFOWm5uN0t4QU0xOUVrOU8ySndNOER3Y2VhVWlDZUJZcWxlc3FpQUFzNERwdTEzdjJyTllyalNuVmwzbEJzX1RUN3hpUDZWZkg0X3VxZmRfYlhhS1M5VDZrLWRxZEJBdFkzSlpFU2NJY2VnRTBGMl9kT2l1aURLbXhLbGtfQXFqWU0wWllEV2RkdkN0TndsbE1iVzZWX1lReXFYZkNTaVJuQUJlXzFQSi1HNjA0Ti1kaVNDcUE4QXBJZU1OUVV3Znk3aHZjdmxMR0pLYjJMUzhPNE51SlcwVGVZcm5DSFl1UGYwb0t2SmJlM0l6TC16TV8ydTNsZlRqanRhbUxsbk9maU82RVpiSmRzeg?oc=5","date":"2025-06-10","type":"trial","source":"globenewswire.com","summary":"Diabetic Nephropathy Clinical Trial Analysis: Key Insights - globenewswire.com","headline":"Diabetic Nephropathy Clinical Trial Analysis: Key Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1BcnlYOWdmV3Uwb3diZEQyVW1VcWJBdVNuQkJFSVFtNHBUSEdGYTFBY1RBYURiNkhfWjBFV184bTdldk1NQ3Z5TVVFV0ZNWlFCTFgyNXk0b3YwR0xfMXhaRlFLWVp2clZ4TjZ5RTdBTXdlbmNy?oc=5","date":"2025-03-24","type":"pipeline","source":"Straits Research","summary":"Scleroderma Therapeutics Market Size, Top Share, Global Trends And Forecast to 2033 - Straits Research","headline":"Scleroderma Therapeutics Market Size, Top Share, Global Trends And Forecast to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPUkRPQjdRMUF4NmVPMUk5SlFJN3RDZExvYmtIZk85RUpFVWJCUWVzT21jSEYxX3NIRTNCV1NhdDZNeE5QYjRxUUVMTjltR05iSEQ3aUxmMlNocEkzSlo2TXFYd05VN185d2Y1MjdGSGJqY1pIZC1lckZOQk9VVDNSN2hTUzFnU3NfWDhaSlcxTDhpZVdmRmFjODltcU9xa1g2UWMwOWdwS3RaUFczblJn?oc=5","date":"2023-10-24","type":"regulatory","source":"Pharmaceutical Technology","summary":"Certa wins FDA orphan drug designation for scleroderma therapy - Pharmaceutical Technology","headline":"Certa wins FDA orphan drug designation for scleroderma therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9IZXJzaWNKOTRZUlNEMzJ4VVkzTzVEWmRGb3JpeWpjVWtZTU90TFIzQW1DaTJWdVQtTDdVRlc5T3J0TmJiSUpjSUV1bnlXU29abjV0Q05kOV9mQ0FZam9rbi1SdllPNUVsbk1rN0U2TWZoSTdFcjd2RFhiNDJDdw?oc=5","date":"2023-02-07","type":"trial","source":"Labiotech.eu","summary":"Certa scleroderma study shows improvement in more than 60% of patients - Labiotech.eu","headline":"Certa scleroderma study shows improvement in more than 60% of patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOWnNGWTNtbU5MRnRlQmhYU3dSZ2JlMGtpMndySTU3bzZMcVF0a1dELXFNT05fV1RyNjZ2d1dsazVYcHF2YlRIVkhpZGZqMndKUlVxZXJ6TjczSE4td2xLTXVpVnFBWTBJNjhBc20tb2t5RmUxNXA1RmtZY3RULUlVeE9YdEI2ZGkzU3JxaVFCTFpTTW96RFF1ZDhtWTlqbWdiZ0tEd2RmcEhTZ3pWTzJUOGZ0alprNXZ3S0NWTjZEd1NSZw?oc=5","date":"2023-02-07","type":"pipeline","source":"drugdiscoverytrends.com","summary":"FT011 yielded significant clinical improvements in more than 60% of scleroderma patients - drugdiscoverytrends.com","headline":"FT011 yielded significant clinical improvements in more than 60% of scleroderma patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNZ0lMNVJMdmwyaFl3NzRFRXZfdjRXWUg1YTVVdlJYZ0QySExEWm5haFp1OS13SnN1UXM2eG1jVjRTaFQ3ODRJSUNpNEVFMkVVdURqa0VwdThKc1NNZllMd1ZDSjBlU3JQQnhKU2ZlbTh2TU92MWtCRHpoRmpWVjlvUE5Id1phQzFGWDlWZ1VuZXZiaXlPU0o5WHMwRExaRzYzWVgyaDhVeUZPVjV1c0RsUmlpal9IQQ?oc=5","date":"2023-02-06","type":"trial","source":"Fierce Biotech","summary":"Ex-Shire drug improves outcomes in autoimmune disease, setting Certa on path to phase 3 - Fierce Biotech","headline":"Ex-Shire drug improves outcomes in autoimmune disease, setting Certa on path to phase 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPRGxSMWVtZjJxQW90WC0weGlSWkw3MFgtWkROOTFrLVFjV2FSV0ZGVEIzY3NmczVLXzd1WVRXcTJteTZna3Jhc2w0U2xMUHJFVzVSa1Y3SE1OamxfMjlFNzFicURvVlhobE55bFhTQWJGR1VNWUFpUlE5S3NldWVlTW9zNnc0ejh3LXh3Q0xSZUY1YWNoYkQxTzZmNWd2cHF5MC02M1BNaDg3X1Vsc1gtdjY1d3kxMUdTaHVIZHdUb0RHcXQ2ZjVGYmxXU3d4dw?oc=5","date":"2021-05-18","type":"pipeline","source":"BioWorld News","summary":"Australian serial entrepreneur Darren Kelly tackles fibrosis yet again in Certa Therapeutics - BioWorld News","headline":"Australian serial entrepreneur Darren Kelly tackles fibrosis yet again in Certa Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBPbERSVm5YQXk0bk43aUNMRy1PYzMtTFNYWTZhQ1JTaERCNmlueTdtanhLeDk0ZzlhQlBUSEN4cjNQdlE3R19CZXB2NFVMS1E0S19tVmhLbnRZV2xqWExURG5Qb0pYRVdTLVhBY3Q1SWk?oc=5","date":"2019-11-26","type":"pipeline","source":"Fierce Biotech","summary":"In conversation with Darren Kelly, CEO of Certa Therapeutics and OccuRx - Fierce Biotech","headline":"In conversation with Darren Kelly, CEO of Certa Therapeutics and OccuRx","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}